Key Drivers
- Strong Liquidity
- Persistent Losses
- Financing Dependence
AIAI Summary
Verastem has evolved into a commercial-stage biotech with a promising high-margin AVMAPKI launch, but investors should require sustained sales growth sufficient to offset roughly $44M in quarterly cash burn while treating October VS-7375 data as the key binary upside catalyst.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Financing Dependence
VSTM has strong liquidity and gross margins, but persistent losses, heavy cash burn, leverage, and reliance on equity financing make the shares high-risk at current valuation.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Resistance tested
- •Support pivotal
VSTM remains bullish above $6.73 but needs a decisive break over $7.38–$7.43; watch $6.82–$6.86 support for trend stability.
Sharp rally to $7.43 during last month increased volatility
Sentiment & News
Key News Insights:
- •Revenue rebound
- •Loss beat
- •Favorable ratings
Verastem's rising AVMAPKI sales and narrower-than-expected loss reinforce a favorable outlook, though analyst views remain mixed.
The results could support positive sentiment toward Verastem shares as commercial momentum improves
Similar Companies in Healthcare
Other companies in the same sector with AI ratings